相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis
Mark D. Cossburn et al.
NEUROLOGY (2013)
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy
Tarek A. Yousry et al.
ANNALS OF NEUROLOGY (2012)
Antibody-independent B cell effector functions in relapsing remitting Multiple Sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity
Sara J. Ireland et al.
AUTOIMMUNITY (2012)
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab
Luisa Klotz et al.
CLINICAL IMMUNOLOGY (2012)
Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis
Roland Martin
CLINICAL IMMUNOLOGY (2012)
Treatment of multiple sclerosis with Anti-CD20 antibodies
Barbara Barun et al.
CLINICAL IMMUNOLOGY (2012)
Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis
Henrik Gensicke et al.
CNS DRUGS (2012)
IL-17: A new actor in IFN-driven systemic autoimmune diseases
Aurelie Ambrosi et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis
Lisa Costelloe et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2012)
Progressive multifocal leukoencephalopathy in autoimmune diseases
Elisabeth Palazzo et al.
JOINT BONE SPINE (2012)
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification
A. Laroni et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2012)
Value of MRI as a surrogate marker for PML in natalizumab long-term therapy
I. Ayzenberg et al.
JOURNAL OF NEUROLOGY (2012)
MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy
Remy Phan-Ba et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
Grant A. Hill-Cawthorne et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab
B. K. Kleinschmidt-DeMasters et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2012)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
Virginia Devonshire et al.
LANCET NEUROLOGY (2012)
Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal
L. Daelman et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings
F. Rinaldi et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis
Aaron E. Miller et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision
Carmen Tur et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod
Sebastian Jander et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
Per Soelberg Sorensen et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
ANTI-JC VIRUS ANTIBODIES IN A LARGE GERMAN NATALIZUMAB-TREATED MS COHORT
Hamid Zahednasab
NEUROLOGY (2012)
SEVERE RELAPSES UNDER FINGOLIMOD TREATMENT PRESCRIBED AFTER NATALIZUMAB
Diego Centonze et al.
NEUROLOGY (2012)
NATALIZUMAB-ASSOCIATED PML IDENTIFIED IN THE PRESYMPTOMATIC PHASE USING MRI SURVEILLANCE
Nicholas F. Blair et al.
NEUROLOGY (2012)
THE EARLIER, THE SMALLER, THE BETTER FOR NATALIZUMAB-ASSOCIATED PML: IN MRI VIGILANCE VERITAS?
Remy Phan-Ba et al.
NEUROLOGY (2012)
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort
A. K. Trampe et al.
NEUROLOGY (2012)
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL
Valerie Rigau et al.
NEUROLOGY (2012)
Impairment of JCV-specific T-cell response by corticotherapy
Caroline Antoniol et al.
NEUROLOGY (2012)
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial
A. J. Coles et al.
NEUROLOGY (2012)
The evidence for a role of B cells in multiple sclerosis
G. Disanto et al.
NEUROLOGY (2012)
Fingolimod for Multiple Sclerosis
Daniel Pelletier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Gary Bloomgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Neutralization of LINGO-1 during In Vitro Differentiation of Neural Stem Cells Results in Proliferation of Immature Neurons
Camilla Loov et al.
PLOS ONE (2012)
Natalizumab Exerts Direct Signaling Capacity and Supports a Pro-Inflammatory Phenotype in Some Patients with Multiple Sclerosis
Thomas F. Benkert et al.
PLOS ONE (2012)
Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1
Carmen Bozic et al.
ANNALS OF NEUROLOGY (2011)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Natalizumab and Impedance of the Homing of CD34+ Hematopoietic Progenitors
Christian Saure et al.
ARCHIVES OF NEUROLOGY (2011)
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Augusto Miravalle et al.
ARCHIVES OF NEUROLOGY (2011)
Human Endogenous Retroviruses in Multiple Sclerosis: Potential for Novel Neuro-Pharmacological Research
F. P. Ryan
Current Neuropharmacology (2011)
Development of anti-CD20 therapy for multiple sclerosis
Beatrix Bartok et al.
EXPERIMENTAL CELL RESEARCH (2011)
The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis
Ithamar Heber Brinkman et al.
EXPERT OPINION ON DRUG SAFETY (2011)
Treating multiple sclerosis with natalizumab
Pietro Iaffaldano et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2011)
Treatment with Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism
Jaime Ramos-Cejudo et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients
A. Kerbrat et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos et al.
LANCET (2011)
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
Ludwig Kappos et al.
LANCET NEUROLOGY (2011)
CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment
Giovanni Frisullo et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis
James P. Sheridan et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Immune reconstitution inflammatory syndrome in natalizumab-associated PML
I. L. Tan et al.
NEUROLOGY (2011)
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
M. Cossburn et al.
NEUROLOGY (2011)
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
P. Vermersch et al.
NEUROLOGY (2011)
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
P. W. O'Connor et al.
NEUROLOGY (2011)
Functional Energetics of CD4+-Cellular Immunity in Monoclonal Antibody-Associated Progressive Multifocal Leukoencephalopathy in Autoimmune Disorders
Aiden Haghikia et al.
PLOS ONE (2011)
IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease
Jarod Zepp et al.
TRENDS IN IMMUNOLOGY (2011)
Natalizumab Dosage Suspension: Are We Helping or Hurting?
Timothy W. West et al.
ANNALS OF NEUROLOGY (2010)
Anti-JC Virus Antibodies: Implications for PML Risk Stratification
Leonid Gorelik et al.
ANNALS OF NEUROLOGY (2010)
Therapeutic Approaches to Multiple Sclerosis An Update on Failed, Interrupted, or Inconclusive Trials of Immunomodulatory Treatment Strategies
Jochen C. Ulzheimer et al.
BIODRUGS (2010)
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity
Joanne L. Jones et al.
BRAIN (2010)
Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
Edward J. Fox
EXPERT REVIEW OF NEUROTHERAPEUTICS (2010)
Treating multiple sclerosis with monoclonal antibodies: a 2010 update
Mathias Buttmann
EXPERT REVIEW OF NEUROTHERAPEUTICS (2010)
Anticipated benefits and surprising effects of daclizumab in multiple sclerosis
Olaf Stuve et al.
LANCET NEUROLOGY (2010)
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
Chris H. Polman et al.
LANCET NEUROLOGY (2010)
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. (vol 9, pg 381, 2010)
D. Wynn et al.
LANCET NEUROLOGY (2010)
Abbott outbids Biogen for Facet's multiple sclerosis antibody
Cormac Sheridan
NATURE BIOTECHNOLOGY (2010)
Passive Immunization with LINGO-1 Polyclonal Antiserum Afforded Neuroprotection and Promoted Functional Recovery in a Rat Model of Spinal Cord Injury
Jun Lv et al.
NEUROIMMUNOMODULATION (2010)
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
Daniel Wynn et al.
LANCET NEUROLOGY (2010)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
Can we get rid of neutralizing antibodies against interferon-β?
M. Buttmann et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers
M. Khademi et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
The role of natalizumab in hematopoietic stem cell mobilization
Frank Neumann et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
Michael Hutchinson et al.
JOURNAL OF NEUROLOGY (2009)
Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment
M. Trojano et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
The late adverse events of rituximab therapy - rare but there!
Ron Ram et al.
LEUKEMIA & LYMPHOMA (2009)
CD19: a promising B cell target for rheumatoid arthritis
Thomas F. Tedder
NATURE REVIEWS RHEUMATOLOGY (2009)
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells
P. Kivisakk et al.
NEUROLOGY (2009)
Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab
Halvard Bonig et al.
BLOOD (2008)
Induction of systemic TNFα in Natalizumab-treated multiple sclerosis
M. Khademi et al.
EUROPEAN JOURNAL OF NEUROLOGY (2008)
Treating multiple sclerosis with monoclonal antibodies
Mathias Buttmann et al.
Expert Review of Neurotherapeutics (2008)
Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients
Raija L. P. Lindberg et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
Anti-glomerular basement membrane disease after alemtuzumab
Menna R. Clatworthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis
Alasdair J. Coles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Colony-stimulating factors in inflammation and autoimmunity
John A. Hamilton
NATURE REVIEWS IMMUNOLOGY (2008)
LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis
Sha Mi et al.
NATURE MEDICINE (2007)
Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models
Haruhisa Inoue et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination
Xinhua Lee et al.
JOURNAL OF NEUROSCIENCE (2007)
LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury
Benxiu Ji et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2006)
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis
Olaf Stuve et al.
ARCHIVES OF NEUROLOGY (2006)
Immune surveillance in multiple sclerosis patients treated with natalizumab
O Stüve et al.
ANNALS OF NEUROLOGY (2006)
Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis
B Bielekova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The window of therapeutic opportunity in multiple sclerosis
AJ Coles et al.
JOURNAL OF NEUROLOGY (2006)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
Brief report - Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
A Langer-Gould et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
G Van Assche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
LINGO-1 negatively regulates myelination by oligodendrocytes
S Mi et al.
NATURE NEUROSCIENCE (2005)
LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex
S Mi et al.
NATURE NEUROSCIENCE (2004)
Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination
JM Antony et al.
NATURE NEUROSCIENCE (2004)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1
BA Kallmann et al.
BRAIN (2000)
分享论文
